血清 茁2-MG、sRAGE 联合 PNI 对初治多发性骨髓瘤患者死亡的 预测价值.

Objective: To investigate the predictive value of serum β2-microglobulin(β2-MG), soluble receptor for advanced glycation end-products(sRAGE) combined with prognostic nutrition index(PNI) for death in patients with primary treatment multiple myeloma(MM). Methods: 80 patients with MM initially diagnosed in Maanshan People's Hospital from January 2018 to January 2020 were selected. Serum β2-MG, sRAGE, albumin and peripheral blood lymphocyte count levels of all patients were detected before treatment, and PNI was calculated. The survival of patients with MM was recorded during the follow-up period of 24 months after discharge. The risk factors affecting the death of patients with MM at 24 months after discharge were analyzed and the clinical value of β2-MG, sRAGE and PNI combined in predicting the death of patients with MM at 24 months after discharge was analyzed. Results: During the follow-up period, 1 case was lost to follow-up, 24 cases died, and 55 cases survived. The serum β2-MG level in the death group was higher than that in the survival group (P＜0.05), and the serum sRAGE level and PNI were lower than those in the survival group (P＜0.05). R-ISS Ⅲ and increased β2-MG levels were risk factors for death in patients with MM within 24 months after discharge (P＜0.05), and increased sRAGE level and PNI were protective factors (P＜0.05). The area under curve of β2-MG, sRAGE and PNI predicting the death of patients with MM within 24 months after discharge were 0.776, 0.720 and 0.717, respectively. The area under curve of combining three indicators predicting the death of patients with MM within 24 months after discharge was 0.890, which was higher than that predicted by individual indicators. Conclusion: Increased serum β2-MG level and decreased sRAGE level and PNI in patients with MM are associated with death within 24 months after discharge. The combination of β2-MG, sRAGE and PNI could effectively assist in evaluating the prognosis of patients with MM. [ABSTRACT FROM AUTHOR]